• Consensus Rating: Buy
  • Consensus Price Target: $56.80
  • Forecasted Upside: -5.32%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$59.99
▲ +15.92 (36.12%)

This chart shows the closing price for MRUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRUS

Analyst Price Target is $56.80
▼ -5.32% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $56.80, with a high forecast of $69.00 and a low forecast of $45.00. The average price target represents a -5.32% upside from the last price of $59.99.

This chart shows the closing price for MRUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Merus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00Low
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00Low
5/24/2024Bank of AmericaBoost TargetBuy ➝ Buy$52.00 ➝ $61.00Low
5/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00Low
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$65.00Low
4/22/2024William BlairReiterated RatingOutperformLow
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00Low
3/28/2024Truist FinancialInitiated CoverageBuy$69.00Low
3/4/2024Needham & Company LLCBoost TargetBuy ➝ Buy$42.00 ➝ $65.00Low
2/29/2024HC WainwrightBoost TargetBuy ➝ Buy$48.00 ➝ $65.00Low
2/29/2024Stifel NicolausBoost TargetBuy ➝ Buy$40.00 ➝ $65.00Low
2/29/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$49.00 ➝ $58.00Low
12/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00Low
11/28/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00Low
11/2/2023Canaccord Genuity GroupInitiated CoverageBuy$45.00Low
11/2/2023Canaccord Genuity GroupInitiated CoverageBuy$45.00Low
10/24/2023Stifel NicolausLower TargetBuy ➝ Buy$45.00 ➝ $40.00Low
9/14/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00Low
8/21/2023TD CowenInitiated CoverageOutperformLow
8/10/2023CitigroupLower TargetBuy ➝ Buy$48.00 ➝ $46.00Low
8/8/2023GuggenheimBoost TargetBuy ➝ Buy$46.00 ➝ $48.00Low
8/8/2023Stifel NicolausBoost TargetBuy ➝ Buy$44.00 ➝ $45.00Low
8/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00Low
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$48.00Low
7/24/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00Low
6/30/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00Low
5/18/2023CitigroupBoost Target$47.00 ➝ $48.00Low
5/5/2023HC WainwrightBoost Target$40.00 ➝ $48.00Low
4/18/2023Stifel NicolausBoost TargetBuy$34.00 ➝ $44.00Low
4/18/2023BMO Capital MarketsBoost Target$47.00 ➝ $49.00Low
4/17/2023SVB SecuritiesBoost TargetOutperform$35.00 ➝ $48.00Low
4/17/2023GuggenheimBoost TargetBuy$38.00 ➝ $45.00Low
4/17/2023CitigroupBoost TargetBuy$38.00 ➝ $47.00Low
4/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$35.00Low
4/14/2023Needham & Company LLCReiterated RatingBuy$33.00Low
4/6/2023Needham & Company LLCReiterated RatingBuy$33.00N/A
4/5/2023CitigroupBoost TargetBuy$30.00 ➝ $38.00Low
3/16/2023BMO Capital MarketsBoost TargetOutperform$46.00 ➝ $47.00Low
3/1/2023Needham & Company LLCLower TargetBuy$35.00 ➝ $33.00Low
3/1/2023EF Hutton Acquisition Co. IReiterated RatingBuy$35.00Low
3/1/2023HC WainwrightBoost TargetBuy$39.00 ➝ $40.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$35.00Low
11/16/2022CitigroupLower TargetBuy$34.00 ➝ $30.00Low
11/4/2022SVB LeerinkLower TargetOutperform$39.00 ➝ $35.00Low
11/4/2022Needham & Company LLCLower TargetBuy$40.00 ➝ $28.00Low
11/4/2022HC WainwrightLower TargetBuy$45.00 ➝ $39.00N/A
10/13/2022SVB LeerinkBoost TargetOutperform$33.00 ➝ $39.00Low
8/17/2022CitigroupLower TargetBuy$37.00 ➝ $34.00Low
8/2/2022Stifel NicolausInitiated CoverageBuy$38.00Low
7/18/2022GuggenheimBoost TargetBuy$44.00 ➝ $46.00Low
5/19/2022CitigroupLower TargetBuy$38.00 ➝ $37.00Low
5/10/2022HC WainwrightReiterated RatingBuyMedium
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$45.00Low
2/10/2022Needham & Company LLCInitiated CoverageBuy$45.00Low
11/12/2021HC WainwrightBoost TargetBuy$30.00 ➝ $45.00Medium
11/3/2021Royal Bank of CanadaBoost TargetSector Perform$21.00 ➝ $33.00High
10/11/2021CitigroupBoost TargetBuy$31.00 ➝ $38.00Medium
10/8/2021SVB LeerinkBoost TargetOutperform$33.00 ➝ $45.00Low
10/7/2021Roth CapitalBoost TargetBuy$32.00 ➝ $40.00High
8/9/2021HC WainwrightReiterated RatingBuy$30.00High
6/11/2021William BlairReiterated RatingBuyLow
6/7/2021CitigroupUpgradeNeutral ➝ BuyHigh
5/9/2021SVB LeerinkReiterated RatingBuy$33.00High
4/8/2021William BlairInitiated CoverageOutperformMedium
3/17/2021Royal Bank of CanadaBoost TargetSector Perform$15.00 ➝ $21.00Low
3/17/2021HC WainwrightBoost TargetBuy$23.00 ➝ $30.00Medium
3/16/2021SVB LeerinkInitiated CoverageOutperform$33.00High
1/19/2021Roth CapitalBoost Target$19.00 ➝ $32.00High
8/7/2020HC WainwrightReiterated RatingBuy$23.00High
7/14/2020HC WainwrightReiterated RatingBuy$23.00High
6/26/2020HC WainwrightInitiated CoverageBuy$23.00High
5/27/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$21.00 ➝ $16.00High
5/18/2020GuggenheimLower TargetBuy$26.00 ➝ $23.00High
5/13/2020Royal Bank of CanadaReiterated RatingBuy$21.00Low
11/20/2019GuggenheimInitiated CoverageBuy$25.00Medium
6/28/2019Roth CapitalInitiated CoverageBuy ➝ Buy$20.00High
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/31/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 6 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/30/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 14 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/29/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/28/2024
  • 10 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
5/28/2024

Current Sentiment

  • 10 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Merus logo
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $59.99
Low: $52.34
High: $61.61

50 Day Range

MA: $44.62
Low: $39.81
High: $59.99

52 Week Range

Now: $59.99
Low: $19.81
High: $61.61

Volume

6,908,100 shs

Average Volume

1,054,404 shs

Market Capitalization

$3.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Merus?

The following Wall Street analysts have issued research reports on Merus in the last twelve months: Bank of America Co., BMO Capital Markets, Canaccord Genuity Group Inc., Citigroup Inc., Guggenheim, HC Wainwright, Needham & Company LLC, Stifel Nicolaus, StockNews.com, TD Cowen, Truist Financial Co., and William Blair.
View the latest analyst ratings for MRUS.

What is the current price target for Merus?

10 Wall Street analysts have set twelve-month price targets for Merus in the last year. Their average twelve-month price target is $56.80, suggesting a possible downside of 5.3%. Truist Financial Co. has the highest price target set, predicting MRUS will reach $69.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $45.00 for Merus in the next year.
View the latest price targets for MRUS.

What is the current consensus analyst rating for Merus?

Merus currently has 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRUS will outperform the market and that investors should add to their positions of Merus.
View the latest ratings for MRUS.

What other companies compete with Merus?

How do I contact Merus' investor relations team?

Merus' physical mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company's listed phone number is (130) 253-8800 and its investor relations email address is [email protected]. The official website for Merus is www.merus.nl. Learn More about contacing Merus investor relations.